ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

GNFT Company Profile and Key Details

NASDAQ : GNFT

Genfit S.A.

$3.19

-0.17-5.06%

At Close 4:00 PM

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

GNFT Stock Price Chart

Stock Price Today

Genfit S.A. (GNFT) stock declined over -5.06%, trading at $3.19 on NASDAQ, down from the previous close of $3.36. The stock opened at $3.25, fluctuating between $3.17 and $3.40 in the recent session.

Stock Snapshot

3.36

Prev. Close

3.25

Open

159.07M

Market Cap

49.87M

Number of Shares

3.1739

Day Low

3.4

Day High

7.98

P/E Ratio

97.1%

Free Float in %

0.4

EPS (TTM)

1.36

Book Value

-1.73

Cash Flow per Share

21.17K

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 07, 2025	3.25	3.40	3.17	3.19	21.17K
Apr 04, 2025	3.38	3.38	3.34	3.36	8.11K
Apr 03, 2025	3.56	3.57	3.39	3.41	12.72K
Apr 02, 2025	3.42	3.50	3.30	3.40	11.52K
Apr 01, 2025	3.53	3.54	3.39	3.52	24.21K
Mar 31, 2025	3.53	3.54	3.32	3.42	20.57K
Mar 28, 2025	3.63	3.68	3.63	3.67	5.24K
Mar 27, 2025	3.57	3.58	3.35	3.55	15.24K
Mar 26, 2025	3.51	3.53	3.38	3.48	12.3K
Mar 25, 2025	3.60	3.60	3.40	3.41	7.63K
Mar 24, 2025	3.56	3.62	3.50	3.53	4.53K
Mar 21, 2025	3.62	3.63	3.62	3.63	920
Mar 19, 2025	3.61	3.61	3.61	3.61	445
Mar 18, 2025	3.65	3.65	3.64	3.64	1.07K
Mar 17, 2025	3.64	3.64	3.64	3.64	20.2K
Mar 14, 2025	3.58	3.71	3.51	3.51	5K
Mar 13, 2025	3.60	3.60	3.50	3.50	1.92K
Mar 12, 2025	3.69	3.69	3.63	3.63	15.36K
Mar 11, 2025	3.62	3.67	3.56	3.58	10.74K
Mar 10, 2025	3.65	3.66	3.57	3.63	19.19K

Contact Details

Loos, 59120

France

Website: https://www.genfit.comContact: 333 201 64000

About Company

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Frequently Asked Questions

What is the current Genfit S.A. (GNFT) stock price?

Genfit S.A. (NASDAQ: GNFT) stock price is $3.19 in the last trading session. During the trading session, GNFT stock reached the peak price of $3.40 while $3.17 was the lowest point it dropped to. The percentage change in GNFT stock occurred in the recent session was -5.06% while the dollar amount for the price change in GNFT stock was -$0.17.

GNFT's industry and sector of operation?

The NASDAQ listed GNFT is part of Biotechnology industry that operates in the broader Healthcare sector. Genfit S.A. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GNFT?

Ms. Emilie Desodt
Vice-Pres of HR
Mr. Jean-Francois Mouney
Co-Founder & Chairman
Mr. Laurent Lannoo
Corporation Sec. & Director of Legal Affairs
Mr. M. Pascal Prigent
Chief Executive Officer
Mr. Pascal Caisey
Chief Operating Officer
Dr. Dean W. Hum Ph.D.
Chief Scientific Officer
Ms. Stefanie Magner
Chief Compliance Officer & Executive Vice President of International Legal Affairs
Mr. Thomas Baetz
Chief Financial Officer
Mr. Jean-Christophe Marcoux
Chief Corporation Affairs Officer, Head of Investor Relations & Head of ESG
Prof. Bart Staels
Co-Founder & Chairman of the Scientific Advisory Board
Dr. Meriam Kabbaj Ph.D.
Chief Technology Officer
Ms. Stefanie Magner J.D.
Chief Compliance Officer & Executive Vice President of International Legal Affairs

How GNFT did perform over past 52-week?

GNFT's closing price is 2.57% higher than its 52-week low of $3.11 where as its distance from 52-week high of $6.42 is -50.34%.

How many employees does GNFT have?

Number of GNFT employees currently stands at 169.

Link for GNFT official website?

Official Website of GNFT is: https://www.genfit.com

How do I contact GNFT?

GNFT could be contacted at phone 333 201 64000 and can also be accessed through its website. GNFT operates from Parc EurasantE, Loos, 59120, France.

How many shares of GNFT are traded daily?

GNFT stock volume for the day was 21.17K shares. The average number of GNFT shares traded daily for last 3 months was 9.61K.

What is the market cap of GNFT currently?

The market value of GNFT currently stands at $159.07M with its latest stock price at $3.19 and 49.87M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	169
Beta	1.07
Sales or Revenue	$28.57M
5Y Sales Change%	258.002%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology